Send a textWhat’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty?Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech Access) to explore specialised commissioning in the NHS and what to expect as we head into 2024.Malcolm Qualie and David Thorne explored:Specialised commissioning in the NHSThe risks and opportunities that devolution to ICBs will bringWhat we can expect to see in the short and longer termHow industry can support ICB leaders through this transitionHow Pharma, Medtech, and Diagnostics companies, whose products come under specialised commissioning, can manage these risks and uncertaintiesLearn more at https://mtechaccess.co.uk/nhs-specialised-commissioning/This episode first broadcast as a live webinar in Decmeber 2023. Subscribe to our newsletter to hear more news, insights and events from Petauri Evidence

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related